Colombo N, Civelli M, Cardinale D, Lamantia G, Colombo A, De Giacomi G, Cipolla C
Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy.
Ecancermedicalscience. 2009;3:147. doi: 10.3332/ecancer.2009.147. Epub 2009 Jun 8.
Anthracycline chemotherapy, which represents the treatment of choice for many hematologic and metastatic cancers, unfortunately carries with it the possibility of both early cardiotoxic phenomena, occuring during chemotherapy, and also late cardiotoxic manifestations, occuring even months or years from the completion of treatment.THE CLINICAL MANIFESTATIONS OF EARLY CARDIOTOXICITY COMMONLY INCLUDE: ventricular premature beats, supraventricular tachycardia, cardiomyopathy and sudden death.This study confirms the necessity for close cardiac monitoring of patients undergoing anthracycline therapy. Such monitoring should not only comprise echocardiographic monitoring for left ventricular systo-diastolic dysfunction, but also electrocardiographic monitoring (QTc) in order to exclude electrophysiological changes possibly related to life threatening arrhythmias (10).
蒽环类化疗药物是许多血液系统癌症和转移性癌症的首选治疗方法，但不幸的是，它既有可能在化疗期间出现早期心脏毒性现象，也有可能在治疗结束数月甚至数年之后出现晚期心脏毒性表现。早期心脏毒性的临床表现通常包括：室性早搏、室上性心动过速、心肌病和猝死。本研究证实了对接受蒽环类治疗的患者进行密切心脏监测的必要性。这种监测不仅应包括对左心室收缩-舒张功能障碍的超声心动图监测，还应包括心电图监测（QTc），以排除可能与危及生命的心律失常相关的电生理变化（10）。
